Phase II Study of Weekly Amrubicin for Refractory or Relapsed Non-small Cell Lung Cancer.
Kitagawa C, Iwasaku M, Kogure Y, Ando M, Yoshioka H, Nishiyama A, Watanabe N, Kunimasa K, Tsubouchi K, Oka S, Saka H.
Kitagawa C, et al. Among authors: tsubouchi k.
In Vivo. 2019 Jan-Feb;33(1):163-166. doi: 10.21873/invivo.11453.
In Vivo. 2019.
PMID: 30587617
Free PMC article.
Clinical Trial.